John L Perez

20080131374, Jun 5, 2008

May 4, 2007

11/800531

John R. Medich - East Hanover NJ, US
Hartmut Kupper - Mutterstadt, DE
Jeffrey D. Kent - Deerfield IL, US
John L. Perez - Doylestown PA, US
Eric H. Sasso - Mountain Lakes NJ, US
Oscar Segurado - Lake Bluff IL, US
George Spencer-Green - Mountain Lakes NJ, US
Theodore Pincus - Hastings-on-Hudson NY, US

A61K 49/00
A61K 39/395
A61K 31/44
A61P 29/00

424 92, 4241721, 514354, 4241331

The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of rheumatoid arthritis in a subject.

20080166348, Jul 10, 2008

Apr 10, 2007

11/786442

Hartmut Kupper - Mutterstadt, DE
Jeffrey D. Kent - Deerfield IL, US
Mary A. Cifaldi - Gurnee IL, US
John L. Perez - Doylestown PA, US
Gerd R. Burmester - Berlin, DE
Philip Mease - Seattle WA, US
Daniel J. Lovell - Cincinnati OH, US
Edward Keystone - Toronto, CA
Arthur Kavanaugh - San Diego CA, US

A61K 39/395
G01N 33/68
A61K 39/09
A61K 39/145
A61P 37/00
A61P 19/02

4241361, 4241581, 436 86, 514 12, 4241331, 4241421, 4242441, 4242091

The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of rheumatoid arthritis in a subject.

20120171123, Jul 5, 2012

Oct 25, 2011

13/280613

John R. Medich - East Hanover NJ, US
Hartmut Kupper - Mutterstadt, DE
John L. Perez - Doylestown PA, US
Jeffrey D. Kent - Deerfield IL, US
Eric H. Sasso - Mountain Lakes NJ, US
Oscar Segurado - Lake Bluff IL, US
George Spencer-Green - Mountain Lakes NJ, US
Theodore Pincus - Hastings-on-Hudson NY, US

A61K 39/395
A61J 1/00
A61K 31/4409
A61P 19/02
A61K 49/00

424 92, 4241581, 514354, 206438

The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of rheumatoid arthritis in a subject.

20220401544, Dec 22, 2022

Sep 24, 2020

17/764153

- New York NY, US
John Lance Perez - Doylestown PA, US
Kathrin Ute Jansen - New York NY, US
Paul Liberator - Holmdel NJ, US
Cuiwen Tan - Ridgewood NJ, US
Thomas Richard Jones - Bluffton SC, US
Johannes Frederik Beeslaar - Sandwich, Kent, GB
Judith Absalon - Bronx NY, US
Jason Douglas Maguire - Chesapeake VA, US
Shannon Lea Harris - Boston MA, US

A61K 39/095
A61P 31/04
A61K 47/02

NEW MATERIAL: Recombinant plasmid pTPGIF2 having a size of 4,660 base pairs and a structure obtained by inserting a DNA having a size of 52 base pairs and containing a sequence coding somatostatin into a BamHI incision site of a plasmid vector pTP70-1 capable or fusing a heteropeptide to a carboxy-terminal of a dihydrofolic acid reductase gene of . USE: Producton of fused protein containing somatostatin.PREPARATION: A somatostatin gene is integrated into a plasmid vector pTP70-1. pTPGIF2 is kept in stable state when introduced into . C600 strain. The . C600 train containing pTPGIF2 is deposited in Fermentation Research institute as FERM BP-1577.

20210101943, Apr 8, 2021

Dec 18, 2020

17/126712

- New York NY, US
Rasappa Gounder Arumugham - Lansdale PA, US
John Erwin Farley - Chapel Hill NC, US
Leah Diane Fletcher - Geneseo NY, US
Shannon Lea Harris - Nanuet NY, US
Kathrin Ute Jansen - New York NY, US
Thomas Richard Jones - New City NY, US
Lakshmi Khandke - Nanuet NY, US
Bounthon Loun - North Reading MA, US
John Lance Perez - Doylestown PA, US
Gary Warren Zlotnick - San Antonio TX, US

C07K 14/22
A61K 39/13
A61K 39/295
A61K 39/00
A61K 39/095
A61K 39/12
A61K 39/39
C12N 7/00

In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

20210085773, Mar 25, 2021

Dec 8, 2020

17/114802

- New York NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Rasappa Gounder Arumugham - Lansdale PA, US
John Erwin Farley - Chapel Hill NC, US
Leah Diane Fletcher - Geneseo NY, US
Shannon Lea Harris - Nanuet NY, US
Thomas Richard Jones - New City NY, US
Lakshmi Khandke - Nanuet NY, US
Bounthon Loun - North Reading MA, US
John Lance Perez - Doylestown PA, US
Gary Warren Zlotnick - San Antonio TX, US

Pfizer Inc. - New York NY

A61K 39/095
A61K 39/00
C07K 14/22
A61K 39/295
A61K 47/64
A61K 39/12
A61K 47/02
A61K 47/22
A61K 47/26

In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

20200405838, Dec 31, 2020

Sep 17, 2020

17/024618

- NEW YORK NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Judith Absalon - New York NY, US
Johannes Frederik Beeslaar - Farnham, GB
David Cooper - Monroe NY, US
John Erwin Farley - Chapel Hill NC, US
Leah Diane Fletcher - Geneseo NY, US
Shannon Lea Harris - Nanuet NY, US
Thomas Richard Jones - Bluffton SC, US
Isis Kanevsky - New York NY, US
Lakshmi Khandke - Nanuet NY, US
Paul Liberator - Holmdel NJ, US
John Lance Perez - Doylestown PA, US
Lynn Marie Phelan - Lake Hiawatha NJ, US
Gary Warren Zlotnick - San Antonio TX, US

PFIZER INC. - NEW YORK NY

A61K 39/095
C07K 14/22
C07K 16/12
A61K 47/18
A61K 47/10
A61K 47/26
A61K 31/7028
A61K 47/64
A61P 31/00
A61K 39/12

In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

20200164056, May 28, 2020

Dec 5, 2019

16/704701

- NEW YORK NY, US
Annaliesa Sybil Anderson - Upper Saddle River NJ, US
Judith Absalon - New York NY, US
Johannes Frederik Beeslaar - Farnham, GB
David Cooper - Monroe NY, US
John Erwin Farley - Chapel Hill NC, US
Leah Diane Fletcher - Geneseo NY, US
Shannon Lea Harris - Nanuet NY, US
Thomas Richard Jones - Bluffton SC, US
Isis Kanevsky - New York NY, US
Lakshmi Khandke - Nanuet NY, US
Paul Liberator - Holmdel NJ, US
John Lance Perez - Doylestown PA, US
Lynn Marie Phelan - Lake Hiawatha NJ, US
Gary Warren Zlotnick - San Antonio TX, US

PFIZER INC. - NEW YORK NY

A61K 39/095
A61P 31/00
A61K 47/64
A61K 31/7028
A61K 47/26
A61K 47/10
A61K 47/18
C07K 16/12
C07K 14/22
A61K 39/12

In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.